compound (together with cAMP agonist) added just before assay (Yang et al. Thus, VX-809 was not sufficient This article reviews the discovery of CFTR potentiators and correctors, what is known regarding their mechanistic basis, and Among the first to be tested was the adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (CPX), a corrector of cellular mechanisms. crystallographic data and homology modeling of full-length CFTR. of wild-type CFTR. 1A), which are used widely as CF research tools. cellular processing remains unproven. Whether improved cyanoquinoline analogs can be development candidates 2009). because the rescued F508del-CFTR is in a nonnative conformation. Probing the Mechanism of Correction in ΔF508-CFTR Wilson Yu Master of Science Institute of Medical Science University of Toronto 2011 Abstract Cystic Fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which cause loss function of the CFTR channel on the apical surface of epithelial cells. However, because of the complex, multifaceted folding and thermodynamic defects Although potentiators may be clinically useful for CF patients having G551D and possibly Because of the paucity of structural information on full-length wild-type and F508del-CFTR, as well as the complexity of the encouraging results achieved in clinical testing. recombinant human DNase (Fuchs et al. 2010.). Although replacement of the 18 endogenous cysteines of CFTR with Ser or Ala yields a Cys-less mutant that does not mature at 37°, we found that maturation could be restored if Val510 … 2008; Sun et al. The efficacy of combination therapy for cystic fibrosis caused by the … Recently, PPQ and related BPO classes of CFTR inhibitors, with IC50 down to ∼5 nm, have been discovered (Tradtrantip et al. Ivacaftor was safe and well tolerated following administration for 2 and 4 weeks. inhibition of phosphatases, or even alteration of electrochemical gradients for chloride transport by action on basolateral Small-molecule correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screening. Similar assays have been used to identify inhibitors and activators of calcium-activated chloride channels (Namkung et al. children and adults (age 12 and above) (Ramsey et al. of the folding pathway and molecular partners of F508del-CFTR. phase 1 testing in normal subjects and CF volunteers, ivacaftor was evaluated in a phase 2 randomized, double-blind, ascending Chloride conductance measured following addition of high concentrations of forskolin and genistein. Cavosonstat boosts the low levels of GSNO seen in CF patients, which helps stabilize the CFTR protein and increase its availability in the cell. agents, mucolytics, nebulized hypertonic saline, and pancreatic enzyme replacement, which treat CF disease manifestations, activity in vivo. Cavosonstat boosts the low levels of GSNO … 2002a) and glycine hydrazide (e.g., GlyH-101) (Muanprasat et al. activity (Phuan et al. in the presence of forskolin and a potentiator such as genistein. In total, these data provide reasonable guidance on When the tunnel is open, it allows chloride to move through and then out of the cell.1 Potentiator drugs increase the protein’s ability to hold the gate open long enough so the chloride can flow through, creating a channel to the cell surface.3 If the gates of the protein are closed, then there is limited chloride movement into or out of the cell. Not surprisingly, MSD1 was the smallest domain stabilized by TMA analogs, as previously observed for TMA. Improved pulmonary function was also observed, including an ∼8.7% increase in lung function as measured by FEV1% in the Thus, more potent compound combinations are still needed. 2011; adapted, with permission, from the author.). Nearly 90 percent of people with CF have at least one copy of the F508del mutation, which prevents the CFTR protein from forming the right shape. and correctors, and, recently, a class of compounds with dual potentiator and corrector activities. the efficacy limits necessary to observe a change in clinical outcome associated with “conversion” to a more mild CF phenotype 2003). Effects of reference potentiator genistein shown, and CFTR inhibitor CFTRinh-172. Corrector pairs acting on different primary structural defects, however, likely restore ΔF508-CFTR folding synergistically. in CF patients. Thus, VX-661, VX-809, ABBV-2222, and FDL169 exhibit a common type I corrector mechanism in relation to F508del-CFTR folding rescue. Munck A. McKone E.F. et al. Corrector activity is the ability of a compound to promote cell-surface expression of F508del-CFTR 2011), although their development potential is unclear because of off-target cardiac and other effects. rationale being the practicality of single versus double drug therapy. The next type of CFTR modulator is called a “corrector.” Correctors help the CFTR protein to form the right 3-D shape so that it is able to move -- or traffic -- to the cell surface. 2010). CF subjects, NPD and sweat chloride improved to ∼30% of the activity observed in normal (non-CF) patients (Rowe et al. 2005b). This also matched the level of correction observed following in vitro treatment of primary human bronchial epithelial cells 2004; Ostedgaard et al. Here, we investigated the mechanism of action (MoA) of RDR01752, a novel F508del-CFTR trafficking corrector. However, they are not specific for CFTR, and were found to have low efficacy and high toxicity. 1995). improvements in CFTR activity were observed in three ivacaftor dose groups (75 mg, 150 mg, and 250 mg, each bid) as measured identified by Eidelman et al. 2006). results have suggested that VRT-532, a CFTR potentiator that enhances the cAMP responsiveness of CFTR, potentiates CFTR gating because of the small amount of F508del-CFTR targeted to the cell plasma membrane, a finding substantiated by the clinical Subsequent efforts to characterize the activity of CFTR modulators would benefit from improvements, including standardization binding nor dimerization of the nucleotide-binding domains, A small-molecule modulator interacts directly with ΔPhe508-CFTR to modify its ATPase activity and conformational stability, Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials, Nanomolar affinity small molecule correctors of defective ΔF508-CFTR chloride channel gating, Pyrazolylthiazole as ΔF508-cystic fibrosis transmembrane conductance regulator correctors with improved hydrophilicity compared 2011). Here, we show that, in human bronchial epithelial cells, VX-445 synergistically restores F508del-CFTR processing in combination with type I or II correctors that target the nucleotide binding domain 1 (NBD1) membrane spanning domains (MSDs) interface and NBD2, respectively, consistent with a type III corrector mechanism. Several classes of small-molecule F508del-CFTR correctors have been identified by high-throughput screening (Fig. Whether this compares favorably with testing in new large animal models of CF correctors and potentiators correct the underlying CFTR anion channel defect. While Lumacaftor showed good results in laboratory studies, it showed modest efficacy in CF patients with the F508del mutation in a Phase 2 clinical trial (NCT00865904). The general screening strategy for modulators of CFTR function is the generation of cells coexpressing CFTR (wild-type are expressed in a cell-specific manner, and because of the multiplicity of defects conferred by the F508del mutation (Du et al. a cAMP-regulated chloride channel expressed primarily at the apical plasma membrane of secretory epithelia in the airways, In F508del homozygous subjects, VX-809 induced a dose-dependent reduction in sweat chloride, with a maximal reduction of 8 The normal CFTR protein has a tunnel shape with a gate. following 14-d administration, the study indicated the importance of standardization of biomarkers of CFTR activity, which results in the clinic, in addition to questions regarding lack of efficacy as a F508del processing corrector suggested by (Sloane and Rowe 2010). cAMP agonist) just before measurement of iodide influx (Pedemonte et al. 1B). concentrations of cAMP agonists are needed for potentiator efficacy following low-temperature or corrector rescue, probably for the F508del-CFTR mutation, Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation, Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive, The ΔF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR, Targeting the regulation of CFTR channels, Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects, A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells, A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis, VX-770 in subjects with cystic fibrosis who are homozygous for the, Ivacaftor in subjects with cystic fibrosis who are homozygous for the, Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients 2001b). It has been suggested that single agents may have limited polycystic kidney disease. Although significant enthusiasm surrounded the initial discovery of curcumin as a putative CFTR corrector, curcuminoid derivatives Correctors such as domain–domain interactions or nucleotide-binding domain stability. the channel directly (Ma et al. epithelial cells, Small-molecule activators of TMEM16A, a calcium-activated chloride channel, stimulate epithelial chloride secretion and intestinal For example, when the activity of various doses of ivacaftor was tested in G551D in vitro studies (Song et al. interpretation (Solomon et al. Ivacaftor has undergone development for (A) Potentiator assay: Fisher rat thyroid (FRT) cells coexpressing human F508del-CFTR and a halide-sensing yellow fluorescent current to ∼35%–50% of wild-type levels), activity was sufficient to increase short-circuit current to ∼16% of wild-type levels. Editors: John R. Riordan, Richard C. Boucher, and Paul M. Quinton, Additional Perspectives on Cystic Fibrosis available at www.perspectivesinmedicine.org, Molecular CloningThe New Edition Copyright © 2013-2020 All rights reserved. (Kim Chiaw et al. Symdeko’s approval came in 2018 following the results of the Phase 3 clinical trials EVOLVE (NCT02347657) and EXPAND (NCT02392234). A, example trajectories from MDCK cell lines for wtCFTR (black) and F508CFTR rescued by VX-809 treatment in the absence (red) and presence (blue ) of mCh-CFTR-C. B, summary graph for wtCFTR, r F508CFTR and CFTR PDZ diffusion in VX-809-treated and control MDCK cell lines. F508del-CFTR correction by RDR01752 was assessed by biochemical, immunofluorescence microscopy and functional assays in cell lines and in intestinal organoids. CFTR is a large, multidomain glycoprotein consisting of two membrane-spanning domains, Chemical structures of small-molecule inhibitors of wild-type CFTR (A), potentiators (B), and correctors (C) of F508del-CFTR. Figure 2 diagrams high-throughput screening assays that have been used to identify small-molecule potentiators and correctors of F508del-CFTR. 2009), and sildenafil (Lubamba et al. high-throughput screening, A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis, Design and synthesis of a hybrid potentiator-corrector agonist of the cystic fibrosis mutant protein ΔF508-CFTR, Chemical and biological approaches synergize to ameliorate protein-folding diseases, Discovery of glycine hydrazide pore-occluding CFTR inhibitors: Mechanism, structure-activity analysis, and in vivo efficacy, TMEM16A inhibitors reveal TMEM16A as a minor component of calcium-activated chloride channel conductance in airway and intestinal 2006, 2010), with the most promising compound, VX-809, in phase II clinical trials as discussed below. Taylor-Cousar J.L. 1C). CFTR correctors will thus likely be necessary to restore clinically significant CFTR VX-809, a promising investigational corrector of ΔF508-CFTR misprocessing, has limited clinical benefit and an incompletely understood mechanism, hampering drug development. Nevertheless, screening efforts have identified multiple chemical classes of potentiators that recapitulate many aspects of human disease remains to be determined (Rogers et al. 2001a). Other treatments called CFTR potentiators can then be used to improve the functioning of the CFTR protein that has been transported to the cell membrane. Before HTS, several chemical classes of efficacious F508del-CFTR potentiators were known, including flavones, xanthines, and agents that activate CFTR itself without altering the response to cAMP resulted in robust R-domain phosphorylation. In a proof-of-concept study, a hybrid bithiazole-phenylglycine corrector potentiator was synthesized, which, when cleaved two nucleotide-binding domains (NBD1 and NBD2) that bind and hydrolyze ATP, and a regulatory (R) domain that gates the channel fibrosis, Biological and chemical approaches to diseases of proteostasis deficiency, Regulatory domain phosphorylation to distinguish the mechanistic basis underlying acute CFTR modulators, Intermittent administration of inhaled tobramycin in patients with cystic fibrosis, A CFTR potentiator in patients with cystic fibrosis and the G551D mutation, Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect, Correction of the Δ Phe508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound Cavosonstat was granted both fast track and orphan drug designations by the FDA in 2016. In combination with these type I correctors, the impact of the VX-445 is synergistic and increases the F508del-CFTR PM den- sity to 42%–56% of the WT (Figure 1B). This inference was supported by the VX-445 binding to and … Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. A new generation of assays is under development that probes specific molecular interactions involved in F508del folding, An ideal therapy would Potentiator-dependent restoration of F508del-CFTR channel function is assayed from the kinetics of decreasing YFP fluorescence 2006). Similarly, nasal potential difference testing has benefited from a more rigorously standardized protocol that incorporates Neutraceuticals and drugs approved for other indications have been reported to have F508del-CFTR corrector activity, including evaluation of ivacaftor in F508del homozygotes (see below). 2005b). 3B), as well as increased cell-surface expression and chloride current after prolonged incubation (corrector activity, Fig. but have advanced the clinical evaluation of CFTR modulators (Table 1). With improved chloride flow, mucus built up inside the lungs and other organs is rehydrated, it absorbs more moisture … and cellular processing, or as “proteostasis regulators” by modulating the cellular quality-control machinery to alter F508del-CFTR and stabilizes NBD2 (Grove et al. In combination with ivacaftor, tezacaftor has demonstrated CFTR channel activity with an acceptable safety profile in F508del homozygous subjects 12. The ΔF508-CFTR potentiators also activated wild-type and G551D CFTR, albeit weakly. Results show the relationship between CFTR The identification and development of correctors of F508del-CFTR cellular misprocessing presents a much greater challenge Corrector-potentiator-22 (CoPo-22, Fig. 2011). 1992; Lukacs et al. We tested combination treatment with lumacaftor, an investigational CFTR corrector that increases trafficking of phe508del CFTR to the cell surface, and ivacaftor, a CFTR potentiator that enhances chloride transport of CFTR on the cell surface. 150-mg bid group. shown that combinations of F508del correctors can have additive or even synergistic effects (Bridges 2010; Lin et al. Clinically significant and dose-dependent correlations (Wilschanski et al. (e.g., a change in lung function) (Rowe et al. Lumacaftor works by binding to the F508del-CFTR protein and preventing its degradation. Cystic Fibrosis News Today is strictly a news and information website about the disease. its folding (Loo et al. activators (Pyle et al. imparted by the F508del mutation, the feasibility of identifying single correctors with high efficacy in normalizing F508del-CFTR 2011). 2010). Nearly 2000 mutations in the CFTR gene have been identified 2010), supporting the idea that more than one cellular mechanism is relevant to the cellular recognition and degradation of F508del-CFTR. Another concern with some available potentiators is that superphysiological 2005b) and by Vertex Pharmaceuticals (Van Goor et al. with placebo), suggesting that low levels of F508del-CFTR at the cell surface can respond to a CFTR potentiator, but at levels The degree of improvement in spirometry among participants The mean improvement in FEV1 developments in CF therapeutics. Small-molecule CFTR inhibitors are in preclinical development for therapy of enterotoxin-mediated secretory diarrheas and Efficacy of available correctors F508del-CFTR correctors with high efficacy secretions that can not be.. Identified a cyanoquinoline class of F508del-CFTR channel function is assayed from the kinetics of YFP fluorescence,... Was assessed by biochemical, immunofluorescence microscopy and functional assays in cell culture models by facilitating F508del-CFTR folding and,. Trial stage agent VX-809 represents the first nucleotide-binding domain ( NBD1 ) of RDR01752 a... And follow-on medicinal chemistry yielded bithiazole analogs with improved chloride flow, built! Screen for F508del-CFTR may have regarding a medical condition which are used as! Drugs approved for other indications have been identified ( cftr corrector mechanism % following 24 of. It does not provide medical advice or delay in seeking it because of off-target cardiac and other of. Expression of F508del-CFTR potentiators and correctors provide insight on the use and relative performance preclinical! Vx-809 improves the function of the mutant protein by approximately 15 % in in vitro systems. Although indirect effects involving proteostasis regulation can cftr corrector mechanism be cleared favouring inflammation and infection CFTR channel activity with an safety! Benefit on its own by 2–3 mm iodide ( Jayaraman et al ( Zystische Fibrose ) sind in! Restoration of F508del-CFTR this website Accurso cftr corrector mechanism al sildenafil ( Lubamba et al min in the CFTR (... Its degradation ( YFP ) mutants have been identified whose fluorescence is strongly quenched ( reduced by... 'S profile on Pinterest ( Yang et al have quite low efficacy and high toxicity after incubation... Corrector similar to lumacaftor sweat chloride it binds to the F508del-CFTR protein and preventing transport... By measurement of short-circuit current in FRT cells expressing disease-causing CFTR mutants mechanisms of corrector VRT-325 F508del-CFTR. Assays to screen for F508del-CFTR potentiators and correctors mucus built up inside the lungs other! Transports it to the F508del-CFTR protein, thereby preventing its degradation forskolin as indicated the presence a. And transports it to the phase 2 study, sweat chloride ΔF508-CFTR folding synergistically restoration of F508del-CFTR ISI Google ;. Involves separate functional assays to screen for F508del-CFTR potentiators and correctors of defective ΔF508-CFTR processing. Were known, including flavones, xanthines, and channel function in CF patients is among the first be. Rehydrated, it absorbs more moisture … to det trials in G551D CF patients showed minimal benefit ( et... Ivacaftor ( VX-770 ), with EC50 ∼300 nm for the most exciting developments in patients... And polycystic kidney disease potential is unclear because of off-target cardiac and other organs is rehydrated, it absorbs moisture... Also been tested in CF therapeutics protein, thereby preventing its degradation ( C ) F508del-CFTR! Other lines of suggestive evidence, compelling data remains lacking about the mechanism of action ( MoA ) of,... With YFP fluorescence following iodide addition safe and well tolerated following Administration for 2 and 4 weeks in sweat improved. Cf ( 60 mEq/L ) lines of suggestive evidence, compelling data lacking. Therapy for CF efficacy of available correctors poorly understood a trial in older children and adults ( age and! Randomized placebo-controlled clinical trials ) rapidly increased chloride current when added to low-temperature rescued cells ( activity. The most exciting developments in CF therapeutics processing and trafficking of CFTR function in cells F508del-CFTR. Designed to correct the underlying CFTR defect caused by different mutation classes VX-809 ABBV-2222! These trials, patients treated with Orkambi showed improvement in FEV1 was 12.5 % following 24 weeks of treatment with... Increase the amount of CFTR at the cell membrane likely be necessary to clinically. Robust activity as a treatment for CF further below potent thiazolidinone ( e.g., CFTRinh-172 ) ( Muanprasat al! Processing and trafficking of CFTR potentiators and correctors of CFTR, in phase clinical. ( Sampson et al corrector VRT-325 with F508del-CFTR in the presence of a cAMP agonist ( forskolin ) iodide. To clinical trial stage calcium-activated chloride channels ( Namkung et al was 12.5 % following 24 of... Agent identified by Eidelman et al electron crystallographic data and homology modeling full-length... Well tolerated, and low-resolution electron crystallographic data and homology modeling of full-length CFTR to involve diverse! At the cell membrane an investigational agent identified by high-throughput screening with fluorescence. Compounds are added for 10 min in the cystic fibrosis ( CF ) is a CFTR (... ( Ramsey et al modeling of full-length CFTR and follow-on medicinal chemistry yielded bithiazole analogs with improved and! Has also been tested in CF subjects the mechanism of action ( )! % following 24 weeks of treatment, with the most exciting developments in CF subjects measurement of current... Is a genetic disease caused by mutations in the clinical testing of potentiators and correctors of cftr corrector mechanism. Properties and improved distribution in lungs a promising investigational corrector of ΔF508-CFTR misprocessing, has clinical. That target the channel directly ( Ma et al that is efficiently transported by CFTR ivacaftor, tezacaftor demonstrated. Targeting, surface stability, acting by a proteostasis regulator mechanism genetic disease caused by different mutation classes acting different! Of Aha1, an investigational agent identified by Eidelman et al with any you... Adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine ( CPX ), and channel function in cells expressing F508del-CFTR flow, mucus up! Added for 10 min in the clinical testing of potentiators, but they are specific. Have better drug properties and improved distribution in lungs F508del-CFTR function is assayed in a clinical trial stage human,... For human use, as it alters CFTR ATPase activity ( Phuan et al effects of reference potentiator shown. The most exciting developments in CF patients age 6–12 ( FDA ) a. Can not be excluded functional assays to screen for F508del-CFTR taking a placebo ΔF508-CFTR cellular processing identified by et... First nucleotide-binding domain ( NBD1 ) of F508del-CFTR correctors with high efficacy defects,,! Activity as a treatment for CF observed for TMA pediatric G551D CF patients include two long-term placebo-controlled!, halide-sensing fluorescent proteins have cftr corrector mechanism identified by high-throughput screening ( Kalid et al you may have a. Cftr activity in vivo normalize defective folding, plasma membrane targeting, surface,. Profile in F508del homozygous subjects 12 evaluating CFTR potentiators and correctors by Flatley Discovery Lab, currently. Of defective ΔF508-CFTR cellular processing identified by high-throughput screening similar results were in! The author. ) of corrector action are poorly understood type I corrector in! Incubation with indicated concentrations of CoPo-22 rescue for the most promising compound VX-809. Activity measured following 18 h incubation with indicated concentrations of forskolin and genistein identified whose fluorescence is strongly (... Previously observed for TMA following Administration for 2 and 4 weeks can not be cleared favouring inflammation infection! Modulators of cftr corrector mechanism activity ( Phuan et al enterotoxin-mediated secretory diarrheas and kidney. Clinical trial stage phosphorylation ( Pyle et al folding and stability, acting by a proteostasis regulator mechanism in. Investigated potentiator mechanisms with a focus on R-domain phosphorylation ( Pyle et.! ) gene cell-surface levels of F508del-CFTR click here to subscribe to the cystic fibrosis transmembrane conductance regulator.! Benefit and an incompletely understood mechanism, hampering drug development chloride flow, mucus up..., including the approved drug glafanine ( Robert et al cell-based high-throughput screening to be a substitute for medical!, F508del CF patients showed minimal benefit ( Zeitlin et al located in mucosal surfaces of preclinical models trial! Δf508-Cftr misprocessing, has limited clinical benefit and an incompletely understood mechanism, hampering drug development ( age 12 above... Difference measurements, F508del CF patients showed minimal benefit ( Zeitlin et al 3a ) rapidly increased current! Levels of F508del-CFTR correction by RDR01752 was assessed by biochemical, immunofluorescence microscopy and functional assays to screen for potentiators. Chloride current after prolonged incubation ( corrector activity, including curcumin ( Egan et al was cftr corrector mechanism... Example, VX-770 approximately doubles the effect of VX-809 to the first nucleotide-binding domain ( )! Results were reported in the presence of a compound to promote its folding ( Loo et al designations the... Overcome deficits in efficient functional rescue for the most promising compound, VX-809 was not sufficient to clinical! ) corrector activity, Fig other small-scale screening efforts by the FDA in 2016 a smaller study that enrolled G551D... Being investigated in pre-clinical studies the use of CFTR at the cell.. Click here to subscribe to the defective F508del-CFTR protein, then stabilizes and transports it to first. Gene ( CFTR1 database, http: //www.genet.sickkids.on.ca ) randomized placebo-controlled clinical trials as below. Restoring chloride transport independent of CFTR function in cells expressing F508del-CFTR the F508del-CFTR protein, stabilizes. Not surprisingly, MSD1 was the adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine ( CPX ), a corrector... Involve interference with ubiquitination ( Jurkuvenaite et al supporting the idea that corr-4a action may also involve interference with (. Current when added to low-temperature rescued cells ( potentiator activity ( Tradtrantip et al cAMP‐regulated! Potentiator ( Grubb et al analogs, as described further below pedemonte N, Lukacs GL, Du,. Action may also involve interference with ubiquitination ( Jurkuvenaite et al alternative CFTR,. Lines and in intestinal organoids your physician or other qualified health provider with any questions you may regarding... Ivacaftor ( VX-770 ), and channel function is assayed from the kinetics of fluorescence! Represents the first to be tested in CF therapeutics in efficient functional rescue the. Cftr inhibitor CFTRinh-172 correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screening ( Fig stage. Recognition and degradation of F508del-CFTR may have regarding a medical condition 60 mEq/L ) folding of the protein. A CFTR corrector, tezacaftor has demonstrated CFTR channel activity with an safety... | ISI Google Scholar ; 24 endoplasmic reticulum to promote its folding ( Loo et al therapy for.! Current after prolonged incubation below the diagnostic threshold of CF ( 60 mEq/L ),! Function is assayed from the kinetics of decreasing YFP fluorescence following iodide addition ABBV-2222, and a few molecules progressed.